Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Cancer

Volumn 121, Issue 13, 2015, Pages 2193-2197

  Ramanathan, Ramesh K ^a,b   McDonough, Shannon L ^c   Kennecke, Hagen F ^d   Iqbal, Syma ^e   Baranda, Joaquina C ^f   Seery, Tara E ^g   Lim, Howard J ^d   Hezel, Aram F ^h   Vaccaro, Gina M ⁱ   Blanke, Charles D ^d,i  

^a UNIVERSITY OF ARIZONA   (United States)

^b MAYO CLINIC   (United States)

^c Statistical Center   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AKT inhibitor; gastric cancer; gastroesophageal junction; MK 2206; phase 2 study

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LUNG INFECTION; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT INTERVAL; RESPIRATORY FAILURE; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL JUNCTION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84931028666     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29363     Document Type: Conference Paper

References (22)

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx. Accessed 10 March, 2015.
2. Wagner AD, Unverzagt S, Grothe W, et al., Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010: CD004064.
3. Ajani JA, Moiseyenko VM, Tjulandin S, et al., Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol. 2007; 25: 3205-3209.
4. Cunningham D, Starling N, Rao S, et al., Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358: 36-46.
5. Bang YJ, Van Cutsem E, Feyereislova A, et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697.
6. Lordick F, Kang YK, Chung HC, et al., Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14: 490-499.
7. Waddell TS, Chau I, Barbachano Y, et al., A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J Clin Oncol. 2012; 30: LBA400.
8. Ohtsu A, Shah MA, Van Cutsem E, et al., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29: 3968-3976.
9. Han Z, Wu K, Shen H, et al., Akt1/protein kinase Bα is involved in gastric cancer progression and cell proliferation. Dig Dis Sci. 2008; 53: 1801-1810.
10. Oki E, Baba H, Tokunaga E, et al., Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005; 117: 376-380.
11. Doi T, Muro K, Boku N, et al., Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010; 28: 1904-1910.
12. Ohtsu A, Ajani JA, Bai YX, et al., Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013; 31: 3935-3943.
13. Pal SK, Reckamp K, Yu H, et al., Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010; 19: 1355-1366.
14. Hirai H, Sootome H, Nakatsuru Y, et al., MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9: 1956-1967.
15. Yap TA, Yan L, Patnaik A, et al., First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011; 29: 4688-4695.
16. Fuchs CS, Tomasek J, Yong CJ, et al., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383: 31-39.
17. Kang JH, Lee SI, Lim do H, et al., Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30: 1513-1518.
18. Wilke H, Muro K, Van Cutsem E, et al., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1224-1235.
19. Sangai T, Akcakanat A, Chen H, et al., Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012; 18: 5816-5828.
20. Soung YH, Lee JW, Nam SW, et al., Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology. 2006; 70: 285-289.
21. Gajria D, Chandarlapaty S,. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011; 11: 263-275.
22. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=MK-2206. Accessed September 5, 2014.